Immunotherapy in triple-negative breast cancer: A literature review and new advances

Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in the management of this malignancy, showing an impact on progression-free survival and overall survival in selected populations. In this review we focused on immunotherapy and its current relevance in the management of TNBC, including various scenarios (metastatic and early -neoadjuvant, adjuvant-), new advances in this subtype and the research of potential predictive biomarkers of response to treatment.

Automated summary

Triple-negative breast cancer is a complex and heterogeneous disease with historically limited treatment options. Immunotherapy has emerged as an important alternative treatment, showing impact on progression-free survival and overall survival in selected populations. Further research is needed to explore potential predictive biomarkers of response to treatment in this subtype of breast cancer.